FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Phase 1 Terminated 12 enrolled Fate Therapeutics

NaSequentialOpen-labelTreatment

Summary

This is a Phase 1 dose-finding study of FT-516 in combination with monoclonal antibodies in participants with advanced solid tumors. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.

Timeline

Start: 2020-09-07
Primary completion: 2023-08-11
Completion: 2023-08-11

Outcome

Outcome not reported

Stopped: “This study was terminated by the Sponsor.”

Publications

Background Zhu H, Blum RH, Bjordahl R, Gaidarova S, Rogers P, Lee TT, Abujarour R, Bonello GB, Wu J, Tsai PF, Miller JS, Walcheck B, Valamehr B, Kaufman DS. Pluripotent stem cell-derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity. Blood. 2020 Feb 6;135(6):399-410. doi: 10.1182/blood.2019000621.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	FT516	Cell therapy	—	—
Background	Avelumab	Monoclonal antibody	—	—
Background	Cyclophosphamide	Other / unclassified	—	—
Background	Fludarabine	Small molecule	—	—
Background	IL-2	Protein / enzyme biologic	—	—